Departments of Nuclear Medicine, .
Urology, AIIMS, .
Nucl Med Commun. 2023 Dec 1;44(12):1135-1143. doi: 10.1097/MNM.0000000000001771. Epub 2023 Oct 5.
We compared diagnostic quality of 68 Ga-PSMA PET/CT imaging focused on the pelvic structures using two furosemide protocols in two different groups of patients.
A total of 55 patients with prostate cancer were retrospectively enrolled in the study. Out of 55, 31 patients were in group 1 (median age: 66 years, Range 44-78 years) in which furosemide injection was given after completion of whole-body 68 Ga-PSMA PET/CT scan and 24 patients were in group 2 (median age: 63.5 years, range: 50-82 years) in which it was given along with the 68 Ga-PSMA injection. In both groups, an initial time point scan (T0 scan) and a delayed time point scan (T1scan) were done. The images were analyzed qualitatively as well as quantitatively.
Quantitatively there was no statistically significant difference between the SUVmax and T:B of prostatic lesion and seminal vesicle invasion (SVI) in both the groups at two time points ( P > 0.05). Early furosemide injection caused a washout of the urinary bladder radiotracer concentration in significantly higher number of patients in group 2 (62.5% vs. 6.45% patients, P < 0.001). There was significant clearance of radiotracer activity from the ureters in group 2 (SUVmax: 9.28 vs. 3.09, P = 0.002).
The simultaneous furosemide and 68 Ga-PSMA injection can reduce the urinary excretion of the tracer and improve the diagnostic confidence of prostatic lesion, SVI and lymph nodal metastasis, along with reducing the scanning time and radiation burden, making this protocol an effective alternative to the present protocol of delayed furosemide injection.
我们比较了两种不同患者组中使用两种呋塞米方案对骨盆结构进行 68Ga-PSMA PET/CT 成像的诊断质量。
共回顾性纳入 55 例前列腺癌患者。其中 31 例患者(中位年龄:66 岁,范围:44-78 岁)在完成全身 68Ga-PSMA PET/CT 扫描后给予呋塞米注射,归入第 1 组;24 例患者(中位年龄:63.5 岁,范围:50-82 岁)在给予 68Ga-PSMA 注射时同时给予呋塞米,归入第 2 组。两组均进行初始时间点扫描(T0 扫描)和延迟时间点扫描(T1 扫描)。图像进行定性和定量分析。
在两个时间点,两组患者前列腺病变和精囊侵犯(SVI)的 SUVmax 和 T:B 无统计学差异(P>0.05)。早期呋塞米注射导致第 2 组患者膀胱放射性示踪剂浓度的洗脱明显更多(62.5%比 6.45%的患者,P<0.001)。第 2 组患者输尿管的放射性示踪剂活性明显清除(SUVmax:9.28 比 3.09,P=0.002)。
同时给予呋塞米和 68Ga-PSMA 注射可以减少示踪剂的尿液排泄,提高前列腺病变、SVI 和淋巴结转移的诊断信心,同时减少扫描时间和辐射负担,使该方案成为延迟注射呋塞米方案的有效替代方案。